REVTORPYK (Gedatolisib): A Brand New Breast Cancer Drug Approved July 2026
REVTORPYK (Gedatolisib): A Brand New Breast Cancer Drug Approved July 2026
Medical Disclaimer: This article is for informational purposes only. It is not medical advice. Do not make changes to your medications without talking to your doctor. REVTORPYK is a prescription drug available only through a licensed healthcare provider.
What Is REVTORPYK?
REVTORPYK (pronounced rev-TOR-pik) is a brand new cancer drug. Its scientific name is gedatolisib. The FDA approved it on July 14, 2026 — just over a week ago.
It treats a type of advanced breast cancer called HR-positive, HER2-negative breast cancer. This is the most common type of breast cancer. It affects about 70% of all breast cancer patients.
REVTORPYK is made by a company called Celcuity. This is their very first drug to ever get FDA approval.
How Does It Work?
Think of cancer cells like a car with a stuck gas pedal. The engine keeps running and the car won't stop. The cancer keeps growing and won't slow down.
In many breast cancers, two "gas pedals" are stuck: one called PI3K and one called mTOR. Both send non-stop "grow" signals to the cancer.
REVTORPYK is the first drug that blocks BOTH pedals at once. That is what makes it special. Most cancer drugs only block one or the other. REVTORPYK blocks both PI3K and mTOR at the same time.
It is called a "pan-PI3K/mTOR inhibitor." That just means it hits both targets.
Who Is It For?
REVTORPYK is for people with:
- HR-positive, HER2-negative advanced breast cancer
- Cancer that got worse after hormone therapy (like letrozole or fulvestrant)
- Tumors that are PIK3CA wild-type (meaning the PI3K gene is not mutated)
It is given together with other cancer drugs. The two approved combinations are:
- REVTORPYK + fulvestrant (two drugs)
- REVTORPYK + fulvestrant + palbociclib (three drugs)
It is not for people whose cancer can be cured with surgery. It is for advanced cancer that has spread or cannot be removed.
Where Does It Stand?
| Stage | Status |
|---|---|
| Lab Discovery | ✓ Complete |
| Preclinical Testing | ✓ Complete |
| Phase 1 Trials (Safety) | ✓ Complete |
| Phase 2 Trials (Effectiveness) | ✓ Complete |
| Phase 3 Trials (VIKTORIA-1) | ✓ Complete |
| FDA Approval | ✓ July 14, 2026 |
| On Market | Coming soon |
The Numbers That Matter
In the VIKTORIA-1 clinical trial, the three-drug combination (REVTORPYK + fulvestrant + palbociclib) reduced the risk of the cancer getting worse or death by 76% compared to standard treatment alone.
That is a very large effect for an advanced breast cancer drug.
About 30,000 Americans are diagnosed with HR+/HER2- PIK3CA wild-type advanced breast cancer each year. REVTORPYK is the first drug specifically approved for this group.
Why Does This Matter For Longevity?
Breast cancer is one of the top causes of death in women. The risk goes up with age. Most breast cancer happens after age 50.
Every drug that gives people more time with advanced cancer is a longevity win. REVTORPYK does not cure cancer. But it can slow it down — sometimes by many months or even years.
It also opens the door to a whole new way of treating cancer: hitting multiple growth signals at once. This "double blockade" strategy could be tried in other cancers too.
Celcuity is already studying REVTORPYK in prostate cancer and other tumor types.
What We Do Not Know Yet
- Real-world effectiveness: Trial results are one thing. How well it works in everyday patients is another. We will not know for a while.
- Long-term side effects: The most common side effects include mouth sores, fatigue, nausea, and low blood counts. Rare but serious effects like severe infections need more time to understand.
- Cost and insurance: Celcuity has not announced the price yet. New cancer drugs often cost $10,000-15,000 per month. Insurance coverage is uncertain for such a new drug.
- PIK3CA mutant patients: The approval is only for PIK3CA wild-type tumors (about 60% of HR+/HER2- patients). Patients with PI3K mutations are not covered. The company hopes to expand the label later.
- Overall survival data: We know it slows progression. We do not yet know if it helps people live longer overall. Those results are still being collected.
The Bottom Line
REVTORPYK is a genuinely new kind of cancer drug. It blocks two growth signals at once, and the FDA approved it last week. For thousands of women with advanced breast cancer, it is a real new option — not just another copy of an old idea.
It is not a cure. But it is a step forward. And in cancer treatment, every step forward counts.
Sources
- Celcuity Press Release: "Celcuity Announces FDA Approval of REVTORPYK (gedatolisib)" — July 14, 2026. Celcuity Investor Relations
- FDA Approval Notice: Gedatolisib plus fulvestrant with or without palbociclib for HR+/HER2- advanced breast cancer — July 14, 2026. FDA.gov
- The American Journal of Managed Care: "FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer" — July 15, 2026.
- Medscape: "Gedatolisib Combo Approved for Advanced Breast Cancer" — July 15, 2026.
- BioWorld: "Celcuity's Revtorpyk wins FDA nod in breast cancer" — July 15, 2026.
- VIKTORIA-1 Clinical Trial: NCT05501886. ClinicalTrials.gov